Brokerage firm CLSA initiates coverage on Atour Lifestyle Holdings with an 'Outperform' rating and a $49 price target, highlighting its unique brand ecosystem and asset-light model as key differentiators in a competitive market.
Despite a mixed analyst outlook, Morgan Stanley projects robust growth for Full Truck Alliance's core commission business, even as overall revenue faces headwinds. The digital freight platform's long-term strategy is gaining favor.
Investment bank Macquarie has raised its rating on NIO Inc. (NYSE:NIO) from Neutral to Outperform, citing better-than-expected fourth-quarter delivery figures and the growing success of its battery subscription model. The firm also increased its price target to $6.10.
While Morgan Stanley maintains an Overweight rating on PDD Holdings, the firm has removed the e-commerce giant from its Top Picks list, citing heightened regulatory scrutiny and a slower-than-expected consumer recovery in China.
Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.
Analysts at Stifel have initiated coverage on sports data giant Sportradar Group AG (NASDAQ: SRAD) with a Buy rating and a $28 price target, citing its dominant market position and favorable industry dynamics as online sports betting consolidates.
Analyst firm Stifel has initiated coverage on sports data giant Genius Sports with a Hold rating, praising its foundational role in the online betting ecosystem but flagging a balanced risk-reward at current levels.
RBC Capital has reaffirmed its confidence in Ascendis Pharma, raising its price target following the company's ambitious 2026 strategic goals, which hinge on sustained momentum for its lead therapy and significant long-term revenue targets.
Despite a recent price target cut by KeyBanc, On Holding AG (NYSE: ONON) remains a top growth pick for 2026, with Goldman Sachs upgrading the stock to Buy. Analysts highlight the brand's global momentum and product strength as key drivers.
Truist Securities has raised its price target for Amer Sports (NYSE: AS), citing the company's clear long-term roadmap and 'durable growth levers' across its portfolio of iconic sports brands. The firm sees a realistic path to earnings per share exceeding $2.50 by fiscal 2030.
Despite a recent 6.8% pullback, AUTO1 Group SE (ETR:AG1) has delivered a staggering 239% return to its shareholders over the past three years, highlighting the potential rewards of holding through market volatility. We examine the underlying business trends and investor sentiment behind the numbers.
The French government has intervened to stop satellite operator Eutelsat from selling its ground antenna assets, framing the move as a defense of European strategic autonomy against rivals like SpaceX's Starlink.
As demand for specialist education soars, private investors—from Abu Dhabi to private equity firms—are capitalizing on a strained system, drawing criticism for extracting profits from vulnerable children and cash-strapped councils.
With key self-assessment deadlines approaching, property investors must navigate a changed landscape of tax reliefs and allowable expenses to minimise their liabilities. Experts urge early preparation to avoid costly surprises.
Despite bearing the brunt of costly natural disasters, Asia-Pacific remains the world's least insured region, with a staggering $64 billion protection shortfall in 2024 alone, threatening economic stability and vulnerable communities.
ResMed reports robust revenue and margin expansion in its fiscal Q2 2026, driven by strong device and mask sales. Management highlights strategic investments in AI-powered patient tools and views GLP-1 medications as a potential catalyst for future demand.
Robert Half International reports a pivotal return to sequential revenue growth in Q4 2025, signaling a potential turning point after a prolonged slump. However, the staffing giant continues to grapple with significant year-over-year declines, highlighting an uneven recovery path for the broader professional labor market.
As global economic headwinds persist, UK investors are turning to dividend-paying stocks for portfolio resilience. We analyze three FTSE-listed companies with strong income credentials and growth potential for the coming year.
PennyMac Mortgage Investment Trust (PMT) closed 2025 with robust earnings, driven by a dramatic expansion in its private-label securitization business. While this growth fueled returns, the company's correspondent lending segment faced pressure, and faster mortgage prepayments impacted servicing rights income.
